CANDLE Syndrome

Source review

Source review underway

Citations and claims are being checked. Treat this page as a draft.

How source review works

On this page

CANDLE is short for chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature. It describes an early-onset autoinflammatory phenotype within the proteasome-associated autoinflammatory syndrome (PRAAS) spectrum. Proteasome dysfunction can drive excessive type I interferon signaling and inflammation, but the responsible genes, inheritance patterns, manifestations, and severity are not identical in every person.

Urgent boundaries

Seek urgent or emergency assessment for difficulty breathing, chest pain, blue or gray color, altered alertness, severe dehydration, a new seizure, or rapid clinical decline. Fever is part of CANDLE/PRAAS for many people, but infection can occur at the same time and may be harder to recognize during immune-modifying treatment. Follow the person's specialist-written fever and illness plan rather than assuming every fever is a flare.

People taking long-term systemic corticosteroids should have clinician-written sick-day and emergency instructions. Vomiting, profound weakness, fainting, confusion, or inability to keep medicine down can signal adrenal crisis and needs emergency care. Long-term corticosteroids should not be stopped abruptly without medical direction.

Rapidly worsening rash with severe pain, swelling around the eyes with visual symptoms, inability to drink, markedly reduced urine, or a sudden change in movement or function warrants prompt specialist review.

Quick reference

Topic Condition-specific guidance
Terminology CANDLE is a clinical phenotype within PRAAS; the terms overlap but are not interchangeable in every context
Biology Proteasome dysfunction with excessive interferon signaling and systemic autoinflammation
Genetics Often biallelic PSMB8 variants, but other proteasome genes and digenic or dominant patterns are documented
Common concerns Early fever and skin inflammation, lipodystrophy, growth difficulty, muscle or joint involvement, anemia, and organ inflammation
Diagnosis Clinical, dermatologic, laboratory, pathologic, and molecular findings interpreted together
AAC No diagnosis-based communication system; assess only demonstrated functional needs

Recognition and diagnosis

Presentation often begins in infancy with recurrent or persistent fever, violaceous or swollen skin lesions, and characteristic eyelid or facial inflammation. Other possible findings include loss or abnormal distribution of body fat, growth difficulty, enlarged liver or spleen, anemia or other cytopenias, muscle inflammation or wasting, joint pain or contractures, headaches, and metabolic or liver complications. The pattern and progression vary, and the diagnosis does not establish a person's developmental or cognitive profile.

CANDLE/PRAAS is autoinflammatory rather than simply autoimmune. Evaluation is usually coordinated by pediatric or adult rheumatology or immunology with dermatology, genetics, and other specialties as indicated. It may include inflammatory and blood counts, metabolic and organ assessment, skin biopsy, interferon-pathway testing in specialist settings, and molecular testing.

Although PSMB8 is a well-established cause, a negative PSMB8 result does not by itself exclude the broader PRAAS spectrum. Pathogenic variants have also been identified in other proteasome subunit or assembly genes, sometimes with digenic or dominant inheritance. The differential includes infection, malignancy, immunodeficiency, and other autoinflammatory or interferon-mediated disorders, so fever and rash alone are not diagnostic.

Management and participation

Care aims to control inflammation, monitor treatment toxicity, protect organs, relieve pain, maintain nutrition and mobility, and support the person's priorities. The plan may involve rheumatology or immunology, dermatology, genetics, primary care, endocrinology or metabolism, hepatology, rehabilitation, nutrition, mental health, and school or workplace teams.

Conventional anti-inflammatory and immunosuppressive treatments, including systemic corticosteroids, may provide incomplete control and can cause substantial long-term harm. In a small NIH expanded-access study, the JAK1/2 inhibitor baricitinib reduced symptoms and corticosteroid exposure for some people with CANDLE and related interferonopathies, while nonresponse and serious infection or kidney-related adverse events also occurred. JAK inhibition is specialist-managed, requires safety monitoring, and should not be inferred as appropriate from the diagnosis alone; regulatory status and access vary.

Physical and occupational therapy, positioning, orthoses, mobility technology, pacing, pain management, and environmental changes should be selected from current findings and goals. Fatigue and inflammatory flares can make performance variable. Support should expand choice and participation rather than presume dependence, cognitive impairment, or a fixed decline.

Communication, feeding, and AAC

CANDLE/PRAAS does not inherently cause a specific speech, language, literacy, or cognitive profile. Communication can nevertheless be affected by pain, fatigue, hearing or vision concerns, motor limitation, school absence, mood, treatment effects, or a co-occurring developmental condition. Assess the relevant domain instead of treating the syndrome label.

Feeding and swallowing evaluation is symptom-led. Coughing or choking, wet voice or breathing, prolonged or exhausting meals, recurrent respiratory illness, dehydration, poor growth, or difficulty managing secretions warrants clinical assessment. Do not prescribe a texture, feeding technique, or tube from the diagnosis alone.

If everyday communication is unreliable or effortful, support a multimodal plan using any effective combination of speech, gesture, sign, writing, communication boards, partner-assisted strategies, or speech-generating technology. Feature matching should examine language and literacy, motor range, contractures, pain, positioning, endurance, vision, hearing, environments, and the person's preferences. Touch, switches, or eye tracking are trial options, not syndrome-based defaults.

Include personally meaningful vocabulary and ways to communicate pain, fever or illness, medication effects, positioning, consent, school or work needs, and emergencies. Preserve a reliable yes/no response, train communication partners, and maintain a low-tech backup when appropriate. See the AAC assessment and acquisition guide and ASHA AAC Practice Portal.

Support and key sources